Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Erectile dysfunction (ED), a condition often overlooked and stigmatized in Africa due to widespread misinformation, affects ...

Viatris (VTRS) stock dips after its experimental therapy for eyelid inflammation fails a Phase 3 trial. Read more here.

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Viatris reported that its MR-139 ophthalmic ointment failed to meet its primary endpoint in a Phase III blepharitis trial, ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Viatris in Egypt, a part of global healthcare company Viatris, announced the launch of Norvasc Val, a combination therapy for ...

Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for ...

A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Discover insights with the "Glaucoma - Global Clinical Trials Review, 2025." This comprehensive report outlines the global scenario of glaucoma clinical trials, offering top-line data by region, ...